European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis
NR2E3), for the treatment of both retinitis pigmentosa (RP) and Leber Congenital amaurosis (LCA).
The prevalence of RP in Europe is estimated at approximately 165,000 patients and the prevalence of LCA in Europe is estimated at approximately 40,000 patients. Globally, the number of people suffering from RP and LCA is estimated to be around 2.0 million and 0.2 million, respectively. We believe the granting of this designation by the European Commission validates the potential of our modifier gene therapy platform to treat many inherited retinal diseases, Chairman of the Board, Chief Executive Officer, and Co-founder of Ocugen.
Bionic eye Tech Teaches his ABCs
News Highlights: Bionic eye Tech Teaches his ABCs
Jens Naumann was 17 when an accident flew a piece of metal off a railroad into his left eye. Three years later, a metal strip from a snowmobile clutch destroyed his right eye, plunging him into total darkness. Naumann’s book Search for Paradise tells of his desperate quest back to the light, primarily as the ‘patient alpha’ of biomedical engineer William Dobelle. In the 1970s, Dobelle had shown that electrically stimulating visual areas of the brain (the visual cortex) caused people to perceive spots of light, or ‘phosphenes’.